Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 1;196(2):67-73.
doi: 10.1016/j.toxlet.2010.03.1120. Epub 2010 Apr 9.

Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties

Affiliations

Constructs of human neuropathy target esterase catalytic domain containing mutations related to motor neuron disease have altered enzymatic properties

Nichole D Hein et al. Toxicol Lett. .

Abstract

Neuropathy target esterase (NTE) is a phospholipase/lysophospholipase associated with organophosphorus (OP) compound-induced delayed neurotoxicity (OPIDN). Distal degeneration of motor axons occurs in both OPIDN and the hereditary spastic paraplegias (HSPs). Recently, mutations within the esterase domain of NTE were identified in patients with a novel type of HSP (SPG39) designated NTE-related motor neuron disease (NTE-MND). Two of these mutations, arginine 890 to histidine (R890H) and methionine 1012 to valine (M1012V), were created in human recombinant NTE catalytic domain (NEST) to measure possible changes in catalytic properties. These mutated enzymes had decreased specific activities for hydrolysis of the artificial substrate, phenyl valerate. In addition, the M1012V mutant exhibited a reduced bimolecular rate constant of inhibition (k(i)) for all three inhibitors tested: mipafox, diisopropylphosphorofluoridate, and chlorpyrifos oxon. Finally, while both mutated enzymes inhibited by OP compounds exhibited altered time-dependent loss of their ability to be reactivated by nucleophiles (aging), more pronounced effects were seen with the M1012V mutant. Taken together, the results from specific activity, inhibition, and aging experiments suggest that the mutations found in association with NTE-MND have functional correlates in altered enzymological properties of NTE.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: JKF and SRR jointly hold patent #7384748 B2 that applies to the use of neuropathy target esterase (NTE) gene analysis for diagnosis of neurologic disease; however, the patent has not been licensed and no royalties have been obtained. RJR is a co-inventor on a patent application #12/121,389 on a nanostructured biosensor containing neuropathy target esterase activity that has potential applications for detection of neuropathic organophosphorus compounds; however, the patent has not been issued and no income has been received. NDH received partial support from a research grant from Dow Chemical Company, and RJR had a research grant and consultancy from Dow, which manufactures chlorpyrifos. The active metabolite, chlorpyrifos oxon, is a compound discussed in the manuscript; however, Dow had no involvement in the study design; collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Figures

Fig 1
Fig 1
Chemical structures of inhibitors. O,O-diethyl-3,4,5-trichloro-2-pyridyl phosphate (chlorpyrifos oxon, CPO), diisopropylphosphorofluoridate (DFP), and N,N′-diisopropylphosphorodiamidofluoridate (mipafox, MIP).
Fig 2
Fig 2
Time course of residual activity of inhibited NEST in aging experiments. Enzymes are shown as column headings: wtNEST = wild type neuropathy target esterase catalytic domain (NEST); R890H = R890H mutant NEST; M1012V = M1012V mutant NEST. Inhibitors are shown as row titles: MIP = mipafox; DFP = diisopropylphosphorofluoridate; CPO = chlorpyrifos oxon. Values for each form of inhibited NEST are expressed as percent uninhibited control. Filled symbols (●) = KF-treated; open symbols (○) = KCl-treated. Data are means ± SEM, n = 3.

Similar articles

Cited by

References

    1. Aldridge WN, Reiner E. Enzyme Inhibitors as Substrates: Interactions of Esterases with Esters of Organophosphorus and Carbamic Acids. North-Holland Publishing; Amsterdam: 1972.
    1. Akassoglou K, Malester B, Xu J, Tessarollo L, Rosenbluth J, Chao MV. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. PNAS. 2004;101:5075–5080. - PMC - PubMed
    1. Atkins J, Glynn P. Membrane association of and critical residues in the catalytic domain of human neuropathy target esterase. J Biol Chem. 2000;275:24477–24483. - PubMed
    1. Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, Coleman MP. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neuroscience. 2005;6:6–32. - PMC - PubMed
    1. Bouldin TW, Cavanagh JB. Organophosphorous neuropathy. I. A teased-fiber study of the spatio-temporal spread of axonal degeneration. Am J Pathol. 1979;94:241–252. - PMC - PubMed

Publication types

MeSH terms